September 27, 2011
Nippon Boehringer Ingelheim’s (NBI) novel anticoagulant Prazaxa (dabigatran), for which the Ministry of Health, Labor and Welfare (MHLW; Korosho ) issued a Blue Letter (safety flash report) because deaths caused by serious bleeding due to adverse drug reactions (ADR) were...read more